SCHEMBL1966131

SCHEMBL1966131

CC(C)(C)OC(=O)N(Cc1ccc(F)cc1)n1cccc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
RIPK1 Q13546 2/20 0.42
KCNQ4 P56696 3/20 0.39
KCNQ5 Q9NR82 3/20 0.39
NR1D1 P20393 1/20 0.39
GRM2 Q14416 1/20 0.39
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964950 0.87 AKT1 (0.46) RIPK1HDAC3HDAC1HDAC2NCOR2
SCHEMBL1966228 0.87 MEN1 (0.41) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL1965400 0.86 GAA (0.40) NR1D1HDAC3HDAC1HDAC2NCOR2
SCHEMBL1965544 0.86 RIPK1 (0.47) RIPK1MEN1KMT2A
SCHEMBL1965931 0.85 L3MBTL1 (0.43) NR1D1TDP1MEN1KMT2A
SCHEMBL1964518 0.82 RIPK1 (0.46) RIPK1
SCHEMBL1964210 0.81 RIPK1 (0.46) RIPK1MEN1KMT2A
SCHEMBL1965415 0.81 GPR119 (0.36) KDM1ARIPK1HDAC3HDAC1HDAC2
SCHEMBL1965084 0.81 CTSB (0.40) HDAC8HDAC3HDAC1HDAC2MEN1
SCHEMBL1966223 0.79 ALDH1A1 (0.42) HDAC6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 KDM1A 660/4885HDAC8 136/4885HDAC6 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.